INTRODUCTION {#s1}
============

Hilar cholangiocarcinoma (HC) is a neoplasm arising from the biliary epithelium at the common hepatic duct bifurcation, and may extend to intrahepatic biliary tree and liver \[[@R1], [@R2]\]. Primary sclerosing cholangitis, hepatolithiasis, biliary parasitic disease, hepatitis, choledochal cysts, and thorotrast exposure have been identified as risk factors associated with the development of HC \[[@R3], [@R4]\]. Despite advances in surgical techniques and instruments, the prognosis of HC patients remains extremely poor, with a 5-year overall survival (OS) rate of 10--44% \[[@R5]--[@R7]\].

Red blood cell distribution width (RDW) is a routine laboratory parameter examined with the complete blood count test that indicates the heterogeneity in the size of circulating erythrocytes. RDW is also a widely used laboratory parameter for inflammatory diseases \[[@R8]\]. Recent studies showed that RDW is correlated with prognosis in several malignances, such as lung cancer \[[@R9]\], prostate cancer \[[@R10]\] esophageal cancer \[[@R11]\] and hepatocellular carcinoma \[[@R12]\]. Beyazit Y et al reported that RDW can be considered as a supportive diagnostic tool in differentiating between benign and malignant causes of obstructive jaundice \[[@R13]\]. However, to our knowledge, no studies regarding the prognostic value of RDW in HC are available.

The purpose of the present study was to investigate the prognostic value of the preoperative RDW in HC patients.

RESULTS {#s2}
=======

The characteristics of the patients are outlined in Table [1](#T1){ref-type="table"}. The 292 enrolled patients, including 161 men and 131 women with a median age of 60 years (20--78 years), underwent radical resection for HC. Pre-operative biliary drainage was performed in 194 (81.9%) of the 237 obstructive jaundice patients, 136 patients underwent percutaneous transhepatic cholangiodrainage (PCTD) and 58 patients underwent endoscopic retrograde cholangiopancreatography (ENBD). Preoperative portal vein embolization was performed in 13 patients.

###### Baseline characteristics of patients with hilar cholangiocarcinoma according to red blood cell distribution width (RDW) levels

  Characteristics                   Total   RDW\<14.95   RDW\>14.95   P value
  --------------------------------- ------- ------------ ------------ ---------
  Gender                                                              0.438
  Male                              161     75           86           
  Female                            131     67           64           
  Age                                                                 0.974
  \<65                              210     102          108          
  \>65                              82      40           42           
  Bismuth-Corlette classification                                     0.567
  I                                 29      12           17           
  II                                35      16           19           
  III                               120     56           64           
  IV                                108     58           50           
  Differentiation                                                     0.154
  Well/moderate                     226     115          111          
  Poor                              66      27           39           
  T stage                                                             0.168
  T1                                10      8            2            
  T2                                216     106          110          
  T3                                60      25           35           
  T4                                6       3            3            
  N stage                                                             0.001
  N0                                196     104          82           
  N1                                106     38           68           
  AJCC stage                                                          0.001
  I                                 11      9            2            
  II                                127     74           53           
  III                               145     55           90           
  IV                                9       4            5            
  Perineural invasion                                                 0.616
  Present                           136     64           72           
  Absent                            156     78           78           
  Portal vein invasion                                                0.252
  Present                           53      22           31           
  Absent                            239     120          119          
  Hepatic artery invasion                                             
  Present                           22      8            14           0.231
  Absent                            270     134          136          
  Tumor size                                                          0.066
  \<30mm                            191     100          91           
  \>30mm                            100     41           59           
  Transfusion                                                         0.586
  Yes                               124     58           66           
  No                                168     84           84           

According to the Bismuth-Corlette classification system, 29 patients (9.9%) were staged as type I, 35 (12.0%) patients as type II, 120 (41.1%) patients as type III and 108 (37.0%) patients as type IV. The radical surgery procedures included extrahepatic bile duct resection (n=22, 7.5%), extrahepatic bile duct resection combined with hepatectomy (n=270, 92.5%, 139 left hemihepatectomy, 3 left trisegmentectomy, 26 mesohepatectomy, 59 right hemihepatectomy, 12 right trisegmentectomy, and 31 caudate lobectomy). Caudate lobectomy was conventionally performed, except for 22 type I patients with sufficient negative margins. The average operative time was 390.8±123.9 min and the median blood loss volume was 500 ml (100--3000 ml). A total of 124 patients underwent intraoperative transfusions.

The ROC curve analysis suggested that the optimal cutoff value for the RDW was 14.95 (Figure [1](#F1){ref-type="fig"}). It indicated that RDW predicts HC prognosis with a sensitivity of 57.6% and a specificity of 77.2 % (AUC = 0.694, 95% CI: 0.621-0.766, P \< 0.001). Of the total of 292 patients, 142 patients (48.6%) were detected with RDW of less than 14.95, while there were 150 patients (51.4%) whose RDW was greater than 14.95.

![Optimized cutoff value was determined for red blood cell distribution width (RDW) using receiver operating characteristic curve (ROC) analysis](oncotarget-08-109468-g001){#F1}

The relationships between RDW and clinical characteristics are shown in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}. Our study indicated that N stage, AJCC stage, albumin (ALB), hemoglobin (HGB), white blood cell (WBC), neutrophil-to-lymphocyte ratio (NLR) and mean corpuscular volume (MCV), in the two groups, show significant differences. There were no significant differences in gender, age, Bismuth-Corlette classification, differentiation, T stage, perineural invasion, portal vein invasion, hepatic artery invasion, tumor size, transfusion, platelet count or operation time between the two groups. Linear correlation analysis revealed that RDW \> 14.95 is associated with higher WBC count, higher NLR, lower ALB and lower HGB (Figure [2](#F2){ref-type="fig"}).

###### Baseline characteristics of patients with hilar cholangiocarcinoma according to red blood cell distribution width (RDW) levels

  Variables              PDW \< 16.55        PDW \> 16.55        P value
  ---------------------- ------------------- ------------------- ----------
  Age (year)             60 (20-78)          59 (20-76)          0.585
  ALB (g/L)              38.8 ± 5.0          36.4 ± 4.7          \< 0.001
  HGB (g/L)              131.0 ± 14.6        121.5 ± 12.3        \< 0.001
  WBC (×10^9^/L)         5.6 (3.47-9.49)     6.16 (3.7-9.90)     0.035
  NLR                    2.61 (0.86-17.54)   3.12 (1.21-17.02)   \< 0.001
  PLT (×10^9^/L)         204.7 ± 74.1        220.0 ± 78.8        0.086
  MCV (%)                93.6 (67.4-107)     92.8 (64.5-104.7)   0.039
  Operation time (min)   392.2 ± 119.3       389.5 ± 128.6       0.855

Data are expressed as means (SD) or median (IQR). ALB, albumin; HGB, hemoglobin; WBC, white blood cell count; NLR, neutrophil-to-lymphocyte ratio; PLT, platelet count; MCV, mean corpuscular volume.

![Correlation analysis of RDW with **(A)** WBC, **(B)** NLR, **(C)** ALB, **(D)** HGB. WBC = white blood cell count, NLR = neutrophil-to-lymphocyte ratio, ALB = albumin, HGB = hemoglobin, RDW = red blood cell distribution width.](oncotarget-08-109468-g002){#F2}

In this cohort, the 5-year OS was 25%. Patients with RDW \> 14.95 had a significantly worse 5-year OS than patients with RDW \< 14.95 (12.0% vs. 38.7%, P \< 0.001). The Kaplan-Meier OS curves showed a significant separation in the two subgroups (Figure [3](#F3){ref-type="fig"}).

![Overall survival (OS) based on red blood cell distribution width (RDW) in hilar cholangiocarcinoma patients with radical resection: the 5-year OS rate in the RDW \< 14.95 group were significantly higher than the RDW \>14.95 group](oncotarget-08-109468-g003){#F3}

Univariate and multivariate analysis were performed and the results were presented in Table [3](#T3){ref-type="table"}. Univariate analysis showed that RDW (P \<0.001), differentiation (P \< 0.001), T stage (P \< 0.001), N stage (P \< 0.001), AJCC stage (P \< 0.001), portal vein invasion (P \< 0.001) and hepatic artery invasion (P = 0.002) significantly influenced OS. All factors with P \< 0.05 in the univariate analysis were included in the Cox regression model, in which RDW (P \< 0.001), differentiation (P = 0.004), N stage (P \< 0.001) and AJCC stage (P =0.023) were independent prognostic risk factors for OS.

###### Univariate and multivariate analysis of overall survival in patients with hilar cholangiocarcinoma

  Variables                 Univariate analysis   Multivariate analysis                         
  ------------------------- --------------------- ----------------------- --------------------- ----------
  Gender                    1.107 (0.847-1.447)   0.445                                         
  Male                                                                                          
  Female                                                                                        
  Age(years)                1.131 (0.840-1.522)   0.417                                         
  \<65                                                                                          
  \>65                                                                                          
  Albumin level(g/L)        0.807 (0.600-1.085)   0.156                                         
  \<35                                                                                          
  \>35                                                                                          
  RDW                       2.267 (1.722-2.984)   \< 0.001                1.755 (1.311-2.349)   \< 0.001
  \< 14.95                                                                                      
  \> 14.95                                                                                      
  Histologic grade          2.213 (1.631-3.004)   \< 0.001                1.591 (1.160-2.183)   0.004
  Well/moderate                                                                                 
  poor                                                                                          
  Bismuth type              1.054 (0.912-1.219)   0.473                                         
  Type I, II                                                                                    
  Type III, IV                                                                                  
  Perineural invasion       1.118 (0.856-1.461)   0.413                                         
  Present                                                                                       
  Absent                                                                                        
  T stage                   2.301 (1.698-3.118)   \< 0.001                0.808 (0.268-2.433)   0.704
  T 1,2                                                                                         
  T 3,4                                                                                         
  N stage                   4.914 (3.633-6.648)   \< 0.001                2.731 (1.564-4.770)   \< 0.001
  N0                                                                                            
  N1                                                                                            
  AJCC stage                4.845 (3.616-6.490)   \< 0.001                2.082 (1.109-3.912)   0.023
  I, II                                                                                         
  III, IV                                                                                       
  Tumor diameter(mm)        1.267 (0.961-1.671)   0.093                                         
  ≤30                                                                                           
  \>30                                                                                          
  Portal vein invasion      2.437 (1.755-3.385)   \< 0.001                2.138 (0.928-4.927)   0.074
  Present                                                                                       
  Absent                                                                                        
  Hepatic artery invasion   2.027 (1.288-3.189)   0.002                   1.395 (0.653-2.980)   0.391
  Present                                                                                       
  Absent                                                                                        

HR, hazard ratio; CI, confidence interval; RDW, red blood cell distribution width.

DISCUSSION {#s3}
==========

The current study indicated that RDW is associated with patients' survival and is an independent risk factor for prognosis in HC.

The RDW is a measure of variability of red blood cell volume, that is routinely examined with the complete blood count and it represents quantitative measure of anisocytosis. An elevated RDW in peripheral blood may be associated with different types of anemias, as well as certain liver disorders and systemic inflammation \[[@R14]\]. Additionally, elevated RDW has also been reported as a predictor of adverse outcomes in patients with myocardial infarction, venous thromboembolism, ischemic stroke and cerebral infarction over a past few years \[[@R14]--[@R17]\]. However, recent studies showed that RDW increased in patients with malignant tumors. Some studies indicated that the RDW was dramatically higher in patients with malignances than in healthy persons \[[@R18]\]. Some researches revealed that the RDW was significantly higher in patients with malignant tumors than in those with benign tumors \[[@R19], [@R20]\], and some reports confirmed that a high RDW was strongly associated with cancer stage and prognosis \[[@R21]\].

The specific mechanism of an elevated RDW in the blood of HC patients is still unknown. The possible mechanisms might involve two aspects: systemic inflammatory response and malnutrition.

Increased RDW values have been reported to be correlated with erythrocyte sedimentation rate (ESR) and high-sensitivity C-reactive protein (CRP) concentration, indicating that the RDW reflects the inflammatory state of the patient \[[@R22]\]. Furthermore, elevated interleukin-6 (IL-6) has been observed in almost all types of tumors acting as a major pro-inflammatory mediator in tumor microenvironment \[[@R23]\]. IL-6 inhibits erythropoietin (EPO) production and downregulates the EPO receptor, ultimately impairing efficient erythropoiesis and causing anisocytosis \[[@R24]\]. Forhecz et al investigated the mechanism of the RDW increase induced by inflammatory reactions and found that inflammatory factors affected iron metabolism, shortened the life of red blood cells, and resulted in the release of large numbers of immature red blood cells from the bone marrow into the peripheral blood circulation in advance; alternatively, inflammatory factors increased the rate of ineffective hematopoiesis in the bone marrow, increased the red blood cell volume heterogeneity in peripheral blood, induced an increase in the RDW, suppressed the stimulating effect of erythropoietin on bone marrow erythroid stem cells, along with preventing the antiapoptotic effect and inhibitory effect of erythropoietin on red blood cell maturation \[[@R25]\]. A growing body of evidence has suggested that systemic inflammatory response plays an important role in cancer progression. Tumor-related inflammatory microenvironment could facilitate tumor growth and metastasis by sustaining proliferation, inhibiting apoptosis, inducing epithelial-to-mesenchymal transition (EMT), initiating angiogenesis, and suppressing host-anti-tumor immunity \[[@R26]\]. As shown in Figure [2](#F2){ref-type="fig"}, higher WBC and higher NLR were associated with higher RDW. This result might support the idea that high levels of RDW reflect the chronic inflammation status of patients with HC.

Malnutrition owing to direct effect of cancer causing loss of appetite and weight can lead to deficiency of various minerals as well as vitamins such as iron, folate and vitamin B12. It is a well-known fact that RDW is affected by deficiencies of these minerals and vitamins \[[@R27]\]. This is in agreement with our results, lower ALB and lower HGB were associated with higher RDW.

In this study, the cutoff value of RDW is 14.95. It is different from other malignant tumors including lung cancer, prostate cancer esophageal cancer and hepatocellular carcinoma. We speculated that the prognosis-related RDW values may vary for different malignancies. However, we believe that the difference in laboratory measures and the number of patients included may affect the cutoff value of RDW. We hope that through multicenter cooperation, we can incorporate more patients, unify the RDW measurement standards, and achieve a more convincing cutoff value of RDW.

Some limitations of the study should also be taken into account when interpreting the results. Firstly, our study was retrospective with inherent limitations in its design. Thus, some clinical bias was inevitable. We also did not collect relevant laboratory data regarding inflammatory factors (such as the ESR, CRP and ILs), EPO, folic acid, vitamin B12 and serum ferritin concentration. These indicators might greatly help to further elucidation of the mechanism of RDW elevation in HC patients (Figure [2](#F2){ref-type="fig"}).

In conclusion, RDW is a simple, inexpensive, routinely measured and automatically reported blood test parameter, which reflects the degree of anisocytosis of red blood cells in peripheral blood. Preoperative elevated RDW in the peripheral blood may be regarded as an indicator of systemic inflammatory response which might facilitate HC growth and metastasis. Current evidence suggests that RDW may have clinical significance in predicting OS after surgery in HC patients.

MATERIALS AND METHODS {#s4}
=====================

Patients selection {#s4_1}
------------------

A total of 292 consecutive patients who underwent radical resection for a pathological diagnosis of HC at the West China hospital between January 2005 and February 2012, were retrospectively enrolled and reviewed. The inclusion criteria were as follows: (1) HC was confirmed by pathology examination; (2) patients underwent radical resection (R0 resection). The exclusion criteria included: (1) patients with gallbladder or intrahepatic cholangiocarcinoma extending to the hilum; (2) recurrent or metastatic tumor; (3) non-radical resection (R1 and R2 resection); (4) hematological disorders, autoimmune diseases, systemic inflammatory diseases, renal disease and other cancer; (5) medical treatment with anti-inflammation and (6) patients with preoperative neoadjuvant (chemotherapy and/or radiation) therapy.

Preoperative workup {#s4_2}
-------------------

Preoperative assessment consisted of medical history, physical examination, laboratory tests and radiography. All patients were evaluated by contrast-enhanced ultrasound, contrast-enhanced computed tomography or magnetic resonance cholangiography along with magnetic resonance cholangiopancreatography to determine the location and extent of the tumor. Biliary drainage, including endoscopic retrograde cholangiopancreatography (ENBD) and percutaneous transhepatic cholangiodrainage (PTCD), was applied in patients having obstructive jaundice with \>85 μmol/L total bilirubin. Preoperative portal vein embolization (PVE) was performed in patients with a future remnant liver (FRL) volume \<40%.

Surgical characteristics of the patients {#s4_3}
----------------------------------------

To achieve negative resection margins, different types of surgical approaches, such as segmental bile duct resection, extrahepatic bile duct resection and en bloc resection of the caudate lobe combined with hepatectomy, were adopted. In addition, standard regional lymph node dissection was performed. The surgery was abandoned if metastases to the distant lymph nodes were diagnosed during surgery. According to American Joint Committee on Cancer (AJCC, 7^th^ edition), the locations of regional lymph nodes are defined as follows: along the common bile duct, cystic duct, portal vein and proper hepatic artery \[[@R28]\]. Vascular resection and reconstruction were performed only when vessels could not be detached from the tumor.

Pathological examination {#s4_4}
------------------------

The pathological evidence of cancer was determined by paraffin sections. All HC included were histopathologically confirmed by experienced pathologists. An R0 resection was defined as the presence of a macroscopically and microscopically tumor-free resection margin. An R1 resection was defined as microscopic evidence of tumor tissue at the resection margin. An R2 resection was defined as macroscopic evidence of tumor tissue at the resection margin.

Follow up {#s4_5}
---------

Whether or not chemotherapy and radiotherapy can benefit HC patients remains controversial. Patients with R0 resection were not treated with postoperative chemotherapy or radiotherapy. All enrolled patients had routine follow-up every three months in the first year and subsequently every six months for at least five years post-surgery. The tumor markers (i.e., serum levels of carbohydrate antigen 19-9 and carcinoembryonic antigen), liver function and ultrasonography were conducted. If there were suspicions of tumor recurrence, contrast-enhanced computed tomography or magnetic resonance imaging were further performed. Tumor recurrence was diagnosed on the basis of the combined findings of typical radiological appearance, quantification of CA19-9 levels, and clinical presentation. The date of the first suspicious radiological finding was recorded as the date of initial disease recurrence.

Statistical analysis {#s4_6}
--------------------

Patients data were retrospectively collected and statistical analyses were performed using SPSS version 20.0 (SPSS Inc. Chicago, IL, USA). The quantitative variables were expressed as mean (SD) if they presented a normal distribution or otherwise as median and range. Qualitative variables were presented in absolute numbers and percentages. Normally distributed continuous data were compared by means of the Student t test, skewed-distributed by the Mann--Whitney U-test and ordinal data were compared in a χ2 test or Fisher's exact test. The optimal cutoff value of RDW was determined by the receiver operating characteristic curve (ROC). Survival was described using the Kaplan--Meier method and differences between subgroups were reviewed with the log-rank test. The multivariate analysis for prognostic factors used a Cox proportional hazards model to analyze variables with P \< 0.05 in the univariate analyses. Two-sided P values \< 0.05 were considered to be statistically significant.
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